Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 24:2025:9987648.
doi: 10.1155/jdr/9987648. eCollection 2025.

Decreased Serum Adipose Triglyceride Lipase Level Is Associated With Renal Function Impairment in Patients With Type 2 Diabetes

Affiliations

Decreased Serum Adipose Triglyceride Lipase Level Is Associated With Renal Function Impairment in Patients With Type 2 Diabetes

Ying Wang et al. J Diabetes Res. .

Abstract

Background: Diagnosing diabetic kidney disease (DKD) remains a significant challenge. Research has increasingly focused on kidney injury resulting from lipid metabolism disorders. Adipose triglyceride lipase (ATGL), a pivotal enzyme in lipolysis, is essential for maintaining lipid metabolism balance. The objective of this study was to assess whether serum ATGL could serve as an early biomarker for DKD. Methods: The study divided 236 participants into four groups: healthy controls (n = 59), Type 2 diabetes mellitus (T2DM) with albumin-to-creatinine ratio (ACR) < 30 mg/g (n = 80), microalbuminuria (L-DKD) with ACR 30-300 mg/g (n = 41), and macroalbuminuria (H-DKD) with ACR ≥ 300 mg/g (n = 56). Relevant clinical data were collected, and serum levels of ATGL, kidney injury molecule-1 (KIM-1), and tumor necrosis factor-1 (TNFR-1) were measured. Various statistical analyses, including Spearman's correlation test, receiver operating characteristic curve analysis, multivariate logistic regression, and restricted cubic spline (RCS), were employed to assess the relationship between serum ATGL levels and renal function impairment in DKD. Results: Serum ATGL levels were notably lower in the T2DM, L-DKD, and H-DKD groups compared to healthy controls. Positive correlations were found between serum ATGL levels and estimated glomerular filtration rates (eGFR), while negative correlations were observed with diabetes duration, hypertension history, hyperlipidemia, urine ACR (UACR), 24-h urine total protein (UTP), serum creatinine (SCr), blood urea nitrogen, uric acid, TNFR-1, and KIM-1/creatinine (KIM-1/Cr) levels (p < 0.05). The receiver operating characteristic curve analysis demonstrated that the diagnostic performance of ATGL, when combined with traditional clinical markers, can enhance sensitivity. When participants were grouped by serum ATGL quartiles, it was observed that higher ATGL levels corresponded with lower UACR, 24 h-UTP, SCr, and TNFR-1 levels and higher eGFR. The odds ratios for elevated UACR and 24 h-UTP decreased, and eGFR increased with higher ATGL quartiles. Both univariate and multivariate logistic regression analyses indicated that serum ATGL is a protective factor against DKD development, even after adjusting for potential confounders. RCS analysis indicated a nonlinear dose-response association between serum ATGL levels and renal function metrics, specifically UACR and eGFR, in patients with DKD. Conclusion: Serum ATGL levels are linked to reduced renal function in T2DM patients. A decline in ATGL levels corresponded with a nonlinear rise in UACR and a drop in eGFR, suggesting that serum ATGL may serve as a potential biomarker for DKD development.

Keywords: Type 2 diabetes mellitus; biomarker; diabetic kidney disease; serum ATGL.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Contents of serum ATGL, urine KIM-1/Cr, and serum TNFR-1 in different groups. (a) The level of serum ATGL in HC group, DM group, L-DKD group, and H-DKD group. (b) The level of urinary KIM-1/Cr in HC group, DM group, L-DKD group, and H-DKD group. (c) The level of serum TNFR-1 in HC group, DM group, L-DKD group, and H-DKD group. Data were expressed as the mean ± SD. ⁣p < 0.05,∗∗p < 0.01.
Figure 2
Figure 2
Correlation between serum ATGL and DKD parameters. (a) Correlation between serum ATGL- and DKD-related parameters (diabetes duration, UACR, 24 h-UTP, SCr, BUN, UA, TNFR-1, and KIM-1/Cr) based on Spearman's correlation test. (b) Sensitivity and specificity based on ROC curve (ATGL, eGFR, and eGFR + ATGL). (c) Sensitivity and specificity based on ROC curve (ATGL, KIM-1/Cr, and KIM-1/Cr + ATGL).
Figure 3
Figure 3
Expression differences of different DKD-related parameters in different serum ATGL quartiles. (a) UACR in different serum ATGL levels. (b) 24 h-UTP in different serum ATGL levels. (c) eGFR in different serum ATGL levels. (d) SCr in different serum ATGL levels. (e) BUN in different serum ATGL levels. (f) UA in different serum ATGL levels. (g) TNFR-1 in different serum ATGL levels. (h) KIM-1/Cr in different serum ATGL levels. Data were expressed as the mean ± SD. ⁣p < 0.05,∗∗p < 0.01.
Figure 4
Figure 4
Forest plot of the relationship between quartiles of serum ATGL levels and DKD-related parameters based on logistic regression.
Figure 5
Figure 5
The restricted cubic spline (RCS) model fitting the association between serum ATGL and renal function. Adjustments were made for sex, age, fatty liver, and smoking. Solid lines represent multivariable adjusted β, and dashed lines represent 95% CIs obtained from restricted cubic spline regression. (a) Dose–response of serum ATGL and eGFR. (b) Dose–response of serum ATGL and UACR.

Similar articles

References

    1. Xue R., Gui D., Zheng L., Zhai R., Wang F., Wang N. Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective. Journal of Diabetes Research . 2017;2017:7. doi: 10.1155/2017/1839809.1839809 - DOI - PMC - PubMed
    1. Umanath K., Lewis J. B. Update on Diabetic Nephropathy: Core Curriculum 2018. American Journal of Kidney Diseases . 2018;71(6):884–895. doi: 10.1053/j.ajkd.2017.10.026. - DOI - PubMed
    1. Anders H. J., Huber T. B., Isermann B., Schiffer M. CKD in Diabetes: Diabetic Kidney Disease Versus Nondiabetic Kidney Disease. Nature Reviews Nephrology . 2018;14(6):361–377. doi: 10.1038/s41581-018-0001-y. - DOI - PubMed
    1. Foreman K. J., Marquez N., Dolgert A., et al. Forecasting Life Expectancy, Years of Life Lost, and All-Cause and Cause-Specific Mortality for 250 Causes of Death: Reference and Alternative Scenarios for 2016-40 for 195 Countries and Territories. Lancet . 2018;392(10159):2052–2090. doi: 10.1016/S0140-6736(18)31694-5. - DOI - PMC - PubMed
    1. Alicic R. Z., Rooney M. T., Tuttle K. R. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology . 2017;12(12):2032–2045. doi: 10.2215/CJN.11491116. - DOI - PMC - PubMed

MeSH terms